Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: In vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model

Oncotarget

Volumn 6, Issue 15, 2015, Pages 12936-12954

  Narayana, Jayaram Lakshmaiah ^a,b   Huang, Han Ning ^b   Wu, Chang Jer ^c   Chen, Jyh Yih ^b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

^c NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial peptide; Helicobacter pylori; Micellization; Tilapia piscidin 4 (TP4)

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOKINE; METRONIDAZOLE; POLYPEPTIDE ANTIBIOTIC AGENT; TILAPIA PISCIDIN 4; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ARGINYLLYSYLASPARTYLVALINE; PEPTIDE FRAGMENT; THYMOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MEMBRANE DAMAGE; MEMBRANE DEPOLARIZATION; MICELLE; MICELLIZATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; TH17 CELL; TOXICITY TESTING; ANIMAL; C3H MOUSE; DISEASE MODEL; DRUG EFFECTS; HELICOBACTER INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RABBIT; RANDOMIZATION;

ANIMALS; ANTI-INFECTIVE AGENTS; DISEASE MODELS, ANIMAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MALE; MICE; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; PEPTIDE FRAGMENTS; RABBITS; RANDOM ALLOCATION; THYMOPOIETINS;

EID: 84931088120     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Marshall BJ and Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1:1311-1315.
2. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI and Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med. 1994; 120:977-981.
3. Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI and Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-1136.
4. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH and Friedman GD. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330:1267-1271.
5. Kusters JG, van Vliet AH and Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006; 19:449-490.
6. Lee YC, Liou JM, Wu MS, Wu CY and Lin JT. Eradication of Helicobacter pylori to prevent gastroduodenal diseases:hitting more than one bird with the same stone. Therap Adv Gastroenterol. 2008; 1:111-120.
7. Correa P and Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007; 133:659-672.
8. Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR and Ibrahim NM. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PLoS One. 2014; 9:e112330.
9. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, Price AB. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Helicobacter. 2005; 10:267-275.
10. Altschuler E. Gastric Helicobacter pylori infection as a cause of idiopathic parkinson disease and non-arteric anterior optic ischemic neuropathy. Med Hypotheses. 1996;47:413-414.
11. Khoshnood A, Hakimi P, Salman-Roghani H and Reza Mirjalili M. Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. J Med Life. 2014;7:254-259.
12. Marin AC, McNicholl AG and Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013; 14:843-861.
13. Mirzaei N, Poursina F, Moghim S, Rahimi E and Safaei HG. The mutation of the rdxA gene in metronidazoleresistant Helicobacter pylori clinical isolates. Adv Biomed Res. 2014; 3:90.
14. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N and Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56:772-781.
15. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005; 3:238-250.
16. Ellison RT, 3rd, Giehl TJ and LaForce FM. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun. 1988;56:2774-2781.
17. Viejo-Diaz M, Andres MT and Fierro JF. Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob Agents Chemother. 2005; 49:2583-2588.
18. Radzishevsky I, Krugliak M, Ginsburg H and Mor A. Antiplasmodial activity of lauryl-lysine oligomers. Antimicrob Agents Chemother. 2007; 51:1753-1759.
19. Herce HD, Garcia AE, Litt J, Kane RS, Martin P, Enrique N, Rebolledo A and Milesi V. Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys J. 2009;97:1917-1925.
20. Huang HN, Pan CY, Chan YL, Chen JY and Wu CJ. Use of the Antimicrobial peptide pardaxin (GE33) to protect against methicillin-resistant Staphylococcus aureus infection in mice with skin injuries. Antimicrob Agents Chemother. 2014; 58:1538-1545.
21. Peters BM, Shirtliff ME and Jabra-Rizk MA. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog. 2010;6:e1001067.
22. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO and Teran LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol. 2010;135:1-11.
23. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A. 1987;84:5449-5453.
24. Sader HS, Fedler KA, Rennie RP, Stevens S and Jones RN. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother. 2004; 48:3112-3118.
25. Silphaduang U and Noga EJ. Peptide antibiotics in mast cells of fish. Nature. 2001; 414:268-269.
26. Noga EJ, Silphaduang U, Park NG, Seo JK, Stephenson J and Kozlowicz S. Piscidin 4, a novel member of the piscidin family of antimicrobial peptides. Comp Biochem Physiol B Biochem Mol Biol. 2009; 152:299-305.
27. Lee SA, Kim YK, Lim SS, Zhu WL, Ko H, Shin SY, Hahm KS and Kim Y. Solution structure and cell selectivity of piscidin 1 and its analogues. Biochemistry. 2007; 46:3653-3663.
28. Sung WS, Lee J and Lee DG. Fungicidal effect and the mode of action of piscidin 2 derived from hybrid striped bass. Biochem Biophys Res Commun. 2008;371:551-555.
29. Peng KC, Lee SH, Hour AL, Pan CY, Lee LH and Chen JY. Five different piscidins from Nile tilapia, Oreochromis niloticus: analysis of their expressions and biological functions. PLoS One. 2012;7:e50263.
30. Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, Tuohy M, Hall G and Bonomo RA. Unexpected challenges in treating multidrug-resistant gram-negative rods: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59:1020-1029.
31. Khara JS, Wang Y, Ke XY, Liu S, Newton SM, Langford PR, Yang YY and Ee PL. Anti-mycobacterial activities of synthetic cationic alpha-helical peptides and their synergism with rifampicin. Biomaterials. 2014; 35:2032-2038.
32. Urban C, Mariano N and Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother. 2010; 54:2732-2734.
33. Nishizawa T, Suzuki H, Suzuki M, Takahashi M and Hibi T. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr. 2012;51:114-116.
34. Sarig H, Goldfeder Y, Rotem S and Mor A. Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl. Antimicrob Agents Chemother. 2011; 55:688-695.
35. Makobongo MO, Gancz H, Carpenter BM, McDaniel DP and Merrell DS. The oligo-acyl lysyl antimicrobial peptide C12K-2β12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob Agents Chemother. 2012; 56:378-390.
36. Alves CS, Melo MN, Franquelim HG, Ferre R, Planas M, Feliu L, Bardaji E, Kowalczyk W, Andreu D, Santos NC, Fernandes MX and Castanho MA. Escherichia coli cell surface perturbation and disruption induced by antimicrobial peptides BP100 and pepR. J Biol Chem. 2010; 285:27536-27544.
37. Berry V, Jennings K and Woodnutt G. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother. 1995; 39:1859-1861.
38. Bode G, Mauch F and Malfertheiner P. The coccoid forms of Helicobacter pylori . criteria for their viability. Epidemiol. Infect. 1993; 111:483-490.
39. Müller M, dela Peña A and Derendorf H. Issues in pharmacokinetics and pharmacodynamics of antiinfective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441-1453.
40. Aoki W and Ueda M. Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals (Basel). 2013;6:1055-1081.
41. Li H, Cheng JW, Yu HY, Xin Y, Tang L and Ma Y. Effect of the antimicrobial peptide D-Nal-Pac-525 on the growth of Streptococcus mutans and its biofilm formation. J Microbiol. Biotechn. 2013; 23:1070-1075.
42. Xiang Z, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R and Covacci A. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun. 1995; 63:94-98.
43. Shahamat M, Alavi M, Watts JE, Gonzalez JM, Sowers KR, Maeder DW and Robb FT. Development of two PCRbased techniques for detecting helical and coccoid forms of Helicobacter pylori. J Clin Microbiol. 2004;42:3613-3619.
44. Rimbara E, Sasatsu M and Graham DY. PCR detection of Helicobacter pylori in clinical samples. Methods Mol Biol (Clifton, NJ). 2013; 943:279-287.
45. Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, Reindl W, Dossumbekova A, Friedrich M, Saur D, Wagner H, Schmid RM and Prinz C. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology. 2006; 131:525-537.
46. Kao JY, Zhang M, Miller MJ, Mills JC, Wang B, Liu M, Eaton KA, Zou W, Berndt BE, Cole TS, Takeuchi T, Owyang SY and Luther J. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology. 2010; 138:1046-1054.
47. OECD. Test No. 423: Acute oral toxicity - acute toxic class method: OECD Publishing.
48. OECD. Test No. 407: Repeated dose 28-day oral toxicity study in rodents: OECD Publishing.
49. OECD. Test No. 405: Acute eye irritation/corrosion: OECD Publishing.
50. OECD. Test No. 406: Skin sensitisation: OECD Publishing.
51. Jones KR, Cha JH and Merrell DS. Who's winning the war? molecular mechanisms of antibiotic resistance in Helicobacter pylori . Curr. Drug Ther. 2008; 3:190-203.
52. Iwao E, Yamamoto K, Yokoyama Y, Hirayama F and Haga K. Potent antibacterial activity of Y-754, a novel benzimidazole compound with selective action against Helicobacter pylori. J Infect Chemother. 2004;10:90-96.
53. McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E and Testerman TL. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob Agents Chemother. 2011; 55:2897-2904.
54. Van Amsterdam K, Bart A and van der Ende A. A Helicobacter pylori tolc efflux pump confers resistance to metronidazole. Antimicrob Agents Chemother. 2005; 49:1477-1482.
55. Hurdle JG, O'Neill AJ, Chopra I and Lee RE. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol. 2011;9:62-75.
56. Pan CY, Chen JC, Sheen JF, Lin TL and Chen JY. Epinecidin-1 has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsis. Antimicrob Agents Chemother. 2014;58:4264-4274.
57. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol. 2013;31:379-382.
58. Chan DI, Prenner EJ and Vogel HJ. Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochimica et biophysica acta. 2006; 1758:1184-1202.
59. Rollema HS, Kuipers OP, Both P, de Vos WM and Siezen RJ. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol. 1995; 61:2873-2878.
60. Tu Z, Young A, Murphy C and Liang JF. The pH sensitivity of histidine-containing lytic peptides. J. Pept. Sci. 2009; 15:790-795.
61. Gray BM, Fontaine CA, Poe SA and Eaton KA. Complex T cell interactions contribute to Helicobacter pylori gastritis in mice. Infect Immun. 2013; 81:740-752.
62. Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T, Yin Z, Wu C, Mao XH, Jia KR, Wang FJ, Guo H, Flavell RA, Zhao Z, Liu KY, Xiao B, Guo Y, et al. Helicobacter pylori -induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol. 2010; 184:5121-5129.
63. Makobongo MO, Kovachi T, Gancz H, Mor A and Merrell DS. In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob Agents Chemother. 2009;53:4231-4239.
64. Lin WJ, Chien YL, Pan CY, Lin TL, Chen JY, Chiu SJ and Hui CF. Epinecidin-1, an antimicrobial peptide from fish (Epinephelus coioides) which has an antitumor effect like lytic peptides in human fibrosarcoma cells. Peptides. 2009; 30:283-290.
65. Huang H-N, Rajanbabu V, Pan C-Y, Chan Y-L, Wu C-J and Chen J-Y. Use of the antimicrobial peptide Epinecidin-1 to protect against MRSA infection in mice with skin injuries. Biomaterials. 2013; 34:10319-10327.
66. Lv Y, Wang J, Gao H, Wang Z, Dong N, Ma Q and Shan A. Antimicrobial properties and membrane-active mechanism of a potential alpha-helical antimicrobial derived from cathelicidin PMAP-36. PLoS One. 2014; 9:e86364.
67. Xie M, Tobin JE, Budde MD, Chen CI, Trinkaus K, Cross AH, McDaniel DP, Song SK and Armstrong RC. Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features. J Neuropath Exp Neur. 2010; 69:704-716.
68. McDaniel DP and Roberson RW. Microtubules are required for motility and positioning of vesicles and mitochondria in hyphal tip cells of Allomyces macrogynus. Fungal Genet Biol. 2000;31:233-244.
69. Wu SP, Huang TC, Lin CC, Hui CF, Lin CH and Chen JY. Pardaxin, a fish antimicrobial peptide, exhibits antitumor activity toward murine fibrosarcoma in vitro and in vivo. Mar Drugs. 2012;10:1852-1872.
70. Obonyo M, Guiney DG, Harwood J, Fierer J and Cole SP. Role of gamma interferon in Helicobacter pylori induction of inflammatory mediators during murine infection. Infect Immun. 2002; 70:3295-3299.
71. James G. Universal bacterial identification by PCR and DNA sequencing of 16S rRNA Gene. 2010:209-214.
72. Sobala GM, Crabtree JE, Dixon MF, Schorah CJ, Taylor JD, Rathbone BJ, Heatley RV and Axon AT. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut. 1991; 32:1415-1418.
73. Colovai AI, Giatzikis C, Ho EK, Farooqi M, Suciu-Foca N, Cattoretti G and Orazi A. Flow cytometric analysis of normal and reactive spleen. Mod Pathol. 2004;17:918-927.
74. Wang Z, Friedrich C, Hagemann SC, Korte WH, Goharani N, Cording S, Eberl G, Sparwasser T and Lochner M. Regulatory T cells promote a protective Th17-associated immune response to intestinal bacterial infection with C. rodentium. Mucosal Immunol. 2014; 7:1290-1301.
75. de Almeida Vaucher R, de Campos Velho Gewehr C, Folmer Correa AP, Sant'Anna V, Ferreira J and Brandelli A. Evaluation of the immunogenicity and toxicity of the antimicrobial peptide P34. Int. J. Pharm. 2011; 421:94-98.
76. Sekizawa J, Yasuhara K, Suyama Y, Yamanaka S, Tobe M and Nishimura M. A simple method for screening assessment of skin and eye irritation. J Toxicol Sci. 1994;19:25-35.